Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
May 4, 2021
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Wenyan Shen, Yan Wang, Hugo Matern, Zhonghao Liu
Abstract: The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.
Type:
Grant
Filed:
September 12, 2018
Date of Patent:
April 13, 2021
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Wenyan Shen, Jie Tang, Yan Wang, Hugo Matern
Abstract: The present disclosure provides methods comprising a glucagon receptor antagonist in combination with an immunotherapeutic agent for treatment of disease.
Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
December 22, 2020
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Abstract: The present disclosure provides binding agents that modulate the interaction between LEAP2 and GHSR. Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use, to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
September 22, 2020
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Daniel David Kaplan, Xuecai Ge, Hui Tian
Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
September 15, 2020
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.
Abstract: Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
April 7, 2020
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
February 18, 2020
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.
Type:
Grant
Filed:
October 22, 2015
Date of Patent:
December 31, 2019
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Darrin Anthony Lindhout, Charles V. Olson
Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Abstract: Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
October 8, 2019
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Alexander Mark Depaoli, Jian Luo, Hui Tian
Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Abstract: Provided are methods of antagonizing the oncogenic activity of FGF19 in a subject. Also provided are methods of treating a FGF19-dependent cancer or tumor, or a symptom thereof in a subject.
Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
June 18, 2019
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar, Geoffrey Horner